CL2018001171A1 - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer - Google Patents
Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncerInfo
- Publication number
- CL2018001171A1 CL2018001171A1 CL2018001171A CL2018001171A CL2018001171A1 CL 2018001171 A1 CL2018001171 A1 CL 2018001171A1 CL 2018001171 A CL2018001171 A CL 2018001171A CL 2018001171 A CL2018001171 A CL 2018001171A CL 2018001171 A1 CL2018001171 A1 CL 2018001171A1
- Authority
- CL
- Chile
- Prior art keywords
- quinolin
- imidazo
- cancer treatment
- compounds
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519568.8A GB201519568D0 (en) | 2015-11-05 | 2015-11-05 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001171A1 true CL2018001171A1 (es) | 2018-10-12 |
Family
ID=55132360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001171A CL2018001171A1 (es) | 2015-11-05 | 2018-05-02 | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20180280377A1 (enExample) |
| EP (1) | EP3370722A1 (enExample) |
| JP (1) | JP2019501873A (enExample) |
| KR (1) | KR20180073684A (enExample) |
| CN (1) | CN108348515A (enExample) |
| AU (1) | AU2016348620B2 (enExample) |
| BR (1) | BR112018007811A2 (enExample) |
| CA (1) | CA3002717A1 (enExample) |
| CL (1) | CL2018001171A1 (enExample) |
| CO (1) | CO2018004933A2 (enExample) |
| CR (1) | CR20180308A (enExample) |
| DO (1) | DOP2018000115A (enExample) |
| GB (1) | GB201519568D0 (enExample) |
| HK (1) | HK1257677A1 (enExample) |
| IL (1) | IL258828A (enExample) |
| MX (1) | MX2018004954A (enExample) |
| NI (1) | NI201800051A (enExample) |
| PE (1) | PE20181346A1 (enExample) |
| PH (1) | PH12018500957A1 (enExample) |
| RU (1) | RU2018120492A (enExample) |
| SV (1) | SV2018005680A (enExample) |
| WO (1) | WO2017076898A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CN111344293A (zh) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2019201283A1 (en) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| WO2020052688A1 (en) * | 2018-09-14 | 2020-03-19 | Suzhou Zanrong Pharma Limited | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF |
| CA3114646C (en) * | 2018-09-30 | 2022-03-08 | Medshine Discovery Inc. | Quinolino-pyrrolidin-2-one derivatives and application thereof |
| CN114258301B (zh) * | 2019-07-30 | 2024-11-08 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| WO2021098734A1 (zh) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
| WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
| CN116056698B (zh) * | 2020-09-21 | 2024-11-19 | 威尚（上海）生物医药有限公司 | 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物 |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN122213088A (zh) * | 2024-12-16 | 2026-06-16 | 北京富龙康泰生物技术有限公司 | 咪唑酮类化合物、及其药物组合物和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| RU2478387C2 (ru) * | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| MA33332B1 (fr) * | 2009-06-04 | 2012-06-01 | Novartis Ag | Dérivés de la 1h-imidazo[4,5-c]quinolinone |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 |
-
2015
- 2015-11-05 GB GBGB1519568.8A patent/GB201519568D0/en not_active Ceased
-
2016
- 2016-11-02 CR CR20180308A patent/CR20180308A/es unknown
- 2016-11-02 BR BR112018007811-5A patent/BR112018007811A2/en not_active Application Discontinuation
- 2016-11-02 WO PCT/EP2016/076416 patent/WO2017076898A1/en not_active Ceased
- 2016-11-02 MX MX2018004954A patent/MX2018004954A/es unknown
- 2016-11-02 HK HK19100041.8A patent/HK1257677A1/zh unknown
- 2016-11-02 JP JP2018522740A patent/JP2019501873A/ja not_active Withdrawn
- 2016-11-02 US US15/772,120 patent/US20180280377A1/en not_active Abandoned
- 2016-11-02 CN CN201680063635.3A patent/CN108348515A/zh active Pending
- 2016-11-02 PE PE2018000610A patent/PE20181346A1/es unknown
- 2016-11-02 AU AU2016348620A patent/AU2016348620B2/en not_active Ceased
- 2016-11-02 EP EP16788723.1A patent/EP3370722A1/en not_active Withdrawn
- 2016-11-02 KR KR1020187015616A patent/KR20180073684A/ko not_active Withdrawn
- 2016-11-02 RU RU2018120492A patent/RU2018120492A/ru not_active Application Discontinuation
- 2016-11-02 CA CA3002717A patent/CA3002717A1/en not_active Abandoned
-
2018
- 2018-04-18 NI NI201800051A patent/NI201800051A/es unknown
- 2018-04-22 IL IL258828A patent/IL258828A/en unknown
- 2018-04-30 SV SV2018005680A patent/SV2018005680A/es unknown
- 2018-05-02 CL CL2018001171A patent/CL2018001171A1/es unknown
- 2018-05-03 DO DO2018000115A patent/DOP2018000115A/es unknown
- 2018-05-03 PH PH12018500957A patent/PH12018500957A1/en unknown
- 2018-05-09 CO CONC2018/0004933A patent/CO2018004933A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108348515A (zh) | 2018-07-31 |
| HK1257677A1 (zh) | 2019-10-25 |
| NI201800051A (es) | 2018-07-30 |
| SV2018005680A (es) | 2018-06-22 |
| RU2018120492A (ru) | 2019-12-05 |
| BR112018007811A2 (en) | 2018-10-30 |
| PE20181346A1 (es) | 2018-08-22 |
| CO2018004933A2 (es) | 2018-08-10 |
| AU2016348620B2 (en) | 2019-05-02 |
| US20180280377A1 (en) | 2018-10-04 |
| WO2017076898A1 (en) | 2017-05-11 |
| MX2018004954A (es) | 2018-07-06 |
| CR20180308A (es) | 2018-10-02 |
| EP3370722A1 (en) | 2018-09-12 |
| IL258828A (en) | 2018-06-28 |
| GB201519568D0 (en) | 2015-12-23 |
| CA3002717A1 (en) | 2017-05-11 |
| AU2016348620A1 (en) | 2018-06-14 |
| KR20180073684A (ko) | 2018-07-02 |
| RU2018120492A3 (enExample) | 2020-01-30 |
| DOP2018000115A (es) | 2018-06-30 |
| JP2019501873A (ja) | 2019-01-24 |
| PH12018500957A1 (en) | 2018-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2018003444A1 (es) | Derivados de adenosina para uso en el tratamiento del cancer. | |
| CL2016001840A1 (es) | Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| IL258828A (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| CL2014003444A1 (es) | Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. |